Mevacor ability to slow progression of atherosclerosis gains FDA approval on Feb. 8.
Executive Summary
MERCK MEVACOR ABILITY TO SLOW ATHEROSCLEROSIS PROGRESSION gained FDA approval on Feb. 8, Merck announced Feb. 9. Mevacor (lovastatin) is the first HMG-CoA reductase inhibitor, lipid-lowering drug to gain approval for that indication. The approval was based on data from three large-scale clinical trials on atherosclerosis: the Canadian Coronary Atherosclerosis Intervention Trial, the Familial Atherosclerosis Treatment Study and the Monitored Atherosclerosis Regression Study.